Flash Therapeutics

About:

Flash is developing an oral compound to prevent AML relapse.

Top Investors: Viva BioInnovator, JMCR Partners, Viva Ventures Biotech Fund

Description:

Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.